top of page

Research overview

    

What I cannot create, I do not understand”

– Richard Feynman

Our reseach focuses on understanding how tumors evade recognition by the immune system. Tumors secrete an arsenal of immunosuppressive proteins that allow them to "hide in plain sight" in the face of a mounting immune response. One of our major goals is to visualize, on the molecular level, how these immunosuppresive proteins inactivate immune cells in the tumor microenvironment. This structural information then serves as a blueprint to guide the engineering of potent immunotherapy drugs. To accomplish these goals, our team uses a combination of directed evolution, computational modeling, structural biology (x-ray crystallography and cryoEM), and cellular signaling assays.

Ongoing projects include:

1) Enhancing T cell immunotherapy with synthetic modulators of Notch signaling

2) Mechanistic studies of T cell inhibition by the immune checkpoint receptor LAG3

3) Development of AI-based in silico screening methods to identify novel immunotherapy drug targets

Structural biology

In vitro characterization

Protein engineering

Novel therapeutics

wt 

v2.0  

[Ligand] 

v1.0  

Cellular receptor activation  

Protein binding kinetics 

bottom of page